Sponsor:
Vertex Pharmaceuticals Incorporated
Code:
NCT07890909
Conditions
Immunoglobulin A Nephropathy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Povetacicept
Sibeprenlimab
Brief summary:
Conditions
Immunoglobulin A Nephropathy
Study ID
NCT07890909
Start date
Nov 13, 2026
Status verified date
Nov, 2026
Completion date
Mar 2, 2028
Anticipated
Primary completion date
Dec 12, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
40 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Povetacicept
Interventions
Povetacicept
Sibeprenlimab
Primary outcome measure
Central contacts
Locations
CTR Oakwater, LLC
Recruiting
Orlando, Florida, United States, 32806
Sponsor
Vertex Pharmaceuticals Incorporated
Last update posted
Nov 17, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.